Drug Profile

JSKN 027

Alternative Names: JSKN027

Latest Information Update: 11 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alphamab Oncology
Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Immunotherapies
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

11 Jul 2025 JSKN 027 is available for licensing as of 11 Jul 2025. https://www.alphamabonc.com/en/company/partnering.html
11 Jul 2025 Alphamab Oncology has patent protection for Alphatecan or linker-payload platform (Alphamab Oncology website, July 2025)
30 Mar 2025 Preclinical trials in Solid tumours in China (unspecified route) (Alphamab oncology pipeline, March 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com